DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,231,185 | -5.0% | 24,723 | 0.0% | 1.45% | -11.9% |
| Q4 2022 | $6,562,000 | +2.8% | 24,723 | 0.0% | 1.64% | -12.3% |
| Q3 2022 | $6,386,000 | +1.9% | 24,723 | 0.0% | 1.87% | +9.3% |
| Q2 2022 | $6,268,000 | -18.6% | 24,723 | -5.8% | 1.71% | +2.8% |
| Q1 2022 | $7,698,000 | -10.9% | 26,242 | -0.0% | 1.67% | -1.5% |
| Q4 2021 | $8,637,000 | +7.3% | 26,252 | -0.8% | 1.69% | +0.4% |
| Q3 2021 | $8,053,000 | +12.6% | 26,453 | -0.7% | 1.68% | +16.9% |
| Q2 2021 | $7,150,000 | +20.6% | 26,642 | +1.1% | 1.44% | +26.3% |
| Q1 2021 | $5,929,000 | -4.6% | 26,342 | -5.9% | 1.14% | -9.7% |
| Q4 2020 | $6,218,000 | +3.2% | 27,990 | 0.0% | 1.26% | -4.5% |
| Q3 2020 | $6,027,000 | +25.0% | 27,990 | +2.7% | 1.32% | +17.5% |
| Q2 2020 | $4,822,000 | +27.8% | 27,267 | 0.0% | 1.13% | +11.7% |
| Q1 2020 | $3,774,000 | -9.5% | 27,267 | +0.4% | 1.01% | -26.8% |
| Q4 2019 | $4,170,000 | +6.3% | 27,167 | 0.0% | 1.38% | -3.2% |
| Q3 2019 | $3,924,000 | +1.1% | 27,167 | +0.0% | 1.42% | -1.5% |
| Q2 2019 | $3,882,000 | +8.3% | 27,161 | 0.0% | 1.44% | +0.1% |
| Q1 2019 | $3,586,000 | +28.0% | 27,161 | 0.0% | 1.44% | +10.7% |
| Q4 2018 | $2,801,000 | -5.1% | 27,161 | 0.0% | 1.30% | +3.1% |
| Q3 2018 | $2,951,000 | +10.1% | 27,161 | 0.0% | 1.26% | +2.8% |
| Q2 2018 | $2,680,000 | +0.8% | 27,161 | 0.0% | 1.23% | +8.1% |
| Q1 2018 | $2,659,000 | +5.5% | 27,161 | 0.0% | 1.14% | +3.0% |
| Q4 2017 | $2,521,000 | +8.2% | 27,161 | 0.0% | 1.10% | +10.1% |
| Q3 2017 | $2,330,000 | +1.7% | 27,161 | 0.0% | 1.00% | +6.5% |
| Q2 2017 | $2,292,000 | -1.3% | 27,161 | 0.0% | 0.94% | 0.0% |
| Q1 2017 | $2,323,000 | +9.9% | 27,161 | 0.0% | 0.94% | +10.6% |
| Q4 2016 | $2,114,000 | -0.9% | 27,161 | -0.2% | 0.85% | +5.2% |
| Q3 2016 | $2,134,000 | -22.4% | 27,219 | 0.0% | 0.81% | -24.0% |
| Q2 2016 | $2,749,000 | +6.1% | 27,219 | -0.3% | 1.07% | +9.0% |
| Q1 2016 | $2,590,000 | +2.1% | 27,299 | 0.0% | 0.98% | -1.3% |
| Q4 2015 | $2,536,000 | +8.4% | 27,299 | -0.6% | 0.99% | -21.7% |
| Q3 2015 | $2,339,000 | -0.5% | 27,455 | 0.0% | 1.27% | -1.0% |
| Q2 2015 | $2,350,000 | -91.5% | 27,455 | +1072.8% | 1.28% | +209.2% |
| Q1 2015 | $27,570,000 | – | 2,341 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |